Applying the use of novel biomarkers for neuroendocrine tumors in the clinic: where are we now?

被引：2
|
作者：
Daskalakis, Kosmas [1 ]
Norlen, Olov [1 ]
Hellman, Per [1 ]
Stalberg, Peter [1 ]
机构：
[1] Uppsala Univ Hosp, Dept Surg Sci, Endocrine Surg Unit, S-75185 Uppsala, Sweden
来源：
INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY | 2019年 / 6卷 / 01期
关键词：
biomarkers; neuroendocrine tumors; prognosis; targeted therapy; PROGNOSTIC MARKERS; CHROMOGRANIN-A; EXPRESSION; ENDOCRINE; DIAGNOSIS; CELLS; LUNG;
D O I：
10.2217/ije-2017-0012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 24 条
  • [11] High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?
    Teresa Alonso-Gordoa
    Ray Manneh
    Enrique Grande
    Javier Molina-Cerrillo
    Current Treatment Options in Oncology, 2022, 23 : 1001 - 1013
  • [12] Localized Well-Differentiated Rectal Neuroendocrine Tumors - Where Are We in 2021?
    Amorim, Larissa Costa
    Ferreira, Artur Rodrigues
    Perez, Rodrigo Oliva
    Peixoto, Renata D'Alpino
    CLINICAL COLORECTAL CANCER, 2022, 21 (01) : E22 - E27
  • [13] From metabolic pathways to biomarkers: where are we now with metabolomics in Alzheimer's disease?
    Trushina, Eugenia
    FUTURE NEUROLOGY, 2013, 8 (05) : 491 - 494
  • [14] Biological features of thoracic aortic diseases. Where are we now, where are we heading to: established and emerging biomarkers and molecular pathways
    Parolari, Alessandro
    Tremoli, Elena
    Songia, Paola
    Pilozzi, Alberto
    Di Bartolomeo, Roberto
    Alamanni, Francesco
    Mestres, Carlos A.
    Pacini, Davide
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2013, 44 (01) : 9 - 23
  • [15] FGFR Inhibitors in Cholangiocarcinoma-A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?
    Chmiel, Paulina
    Geca, Katarzyna
    Rawicz-Pruszynski, Karol
    Polkowski, Wojciech P.
    Skorzewska, Magdalena
    CELLS, 2022, 11 (23)
  • [16] Digital pathology in clinical use: where are we now and what is holding us back?
    Griffin, Jon
    Treanor, Darren
    HISTOPATHOLOGY, 2017, 70 (01) : 134 - 145
  • [17] The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?
    Cinque, Alessandra
    Capasso, Anna
    Vago, Riccardo
    Lee, Michael W.
    Floris, Matteo
    Trevisani, Francesco
    BIOMEDICINES, 2022, 10 (01)
  • [18] Established and novel circulating neuroendocrine tumor biomarkers for diagnostic, predictive and prognostic use
    Tsoli, Marina
    Koumarianou, Anna
    Angelousi, Anna
    Kaltsas, Gregory
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (05)
  • [19] An Update on Novel Therapeutic Warfronts of Extracellular Vesicles (EVs) in Cancer Treatment: Where We Are Standing Right Now and Where to Go in the Future
    Khawar, Muhammad Babar
    Abbasi, Muddasir Hassan
    Siddique, Zerwa
    Arif, Amin
    Sheikh, Nadeem
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2019, 2019
  • [20] Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future
    Raphael, Itay
    Webb, Johanna
    Stuve, Olaf
    Haskins, William
    Forsthuber, Thomas
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (01) : 69 - 91
123